Galderma’s Nemluvio gains FDA nod for moderate-to-severe atopic dermatitis
Galderma has achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) approval of Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients ... Read More
Sun Pharma gains Australian approval for Acne treatment Winlevi
Sun Pharmaceutical Industries Limited (Sun Pharma) has achieved a significant milestone in dermatology with the Australian Therapeutic Goods Administration (TGA)'s recent approval of Winlevi (clascoterone ... Read More
LEO Pharma showcases promising results from DELTA 3 trial at AAD Congress
In a significant development within the field of medical dermatology, LEO Pharma A/S, a global leader renowned for its commitment to advancing dermatological care, presented ... Read More
LEO Pharma secures global rights to JW1601 in $402m deal with JW Pharmaceutical
LEO Pharma, a leading Danish pharmaceutical company, has acquired global exclusive rights to the atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP), in a significant ... Read More